Annual Index Index to Volume 10 The index to Volume 10 is composed of three parts: a subject Pharmacy, as well as selected letters and news reports. The subject index, an author index, and an advertising index. index also notes all regular columns and, under the respective The subject index is made up mainly of terms constructed by column headings, the titles of items in the “News,” “Therapy International Pharmaceutical Abstracts. The IPA index is an alpha- Consultation,” “Letters,” “Editorials,” and “Book Reviews” sec- betical, open-ended, controlled-vocabulary index that makes use tions. The subject index also contains, under the heading “Correc- of standardized headings. (The primary index terms for each ar- tion Notices,” the title and issue of publication of items for which ticle are listed routinely in Clinical Pharmacy as “index terms” after corrections were printed, as well as the page numbers on which abstracts.) IPA covers all authored papers and editorials in Clinical the corrections appear. Issue Pages Issue Pages January 1-80 July 483-566 February 81-160 August 567-650 March 161-246 September 651-730 April 247-318 October 731-806 May 319-404 November 807-890 June 405-482 December 891-990 Subject Index A Absorption Ambulatory care; hypertension; monitoring, devices, Antibiotics glyburide; effects, age, 532 assessment, 175 Mycobacterium avium complex; therapy, AIDS, review, triazolam; interactions, ranitidine, 539 Amikacin 280 Acetaminophen Mycobacterium avium complex; therapy, AIDS, review, imipenem; susceptibility, amikacin-resistant isolates, osteoarthritis; therapy, geriatrics, ulcer history, 740 280 in vitro, 544 pain; therapy, codeine allergies, 658 resistance; gram-negative bacteria, in vitro, 544 vancomycin; dosage guidelines, neonates, 129 poisoning; overdose, acetylcysteine therapy, 765 Amino acids; Alzheimer’s disease; therapy, mechanism vancomycin hydrochloride; blood levels, half-life, Acetazolamide; epilepsy; therapy, review, 335 of action, review, 447 hepatic and renal dysfunction, 297 Acetimidoquinone; metabolites; acetaminophen, toxic- Aminoglycosides Antibodies; monoclonal; radionuclides, immunother- ity, 765 amikacin; Mycobacterium avium complex, AIDS, 280; apy, neoplasms, 359 Acetylcholinesterase inhibitors; Alzheimer’s disease; resistance, gram-negative bacteria, in vitro, 544 Anticoagulants therapy, mechanism of action, review, 447 gentamicin; dosage predictions, pharmacokinetics, heparin; i.v. infusion sites, toxicity, 630; thromboem- Acetylcysteine; therapy; acetaminophen overdose, 765 methodology, 706; renal function estimation, 931; bolism therapy, guidelines, 503 N-Acetylimidoquinone, see Acetimidoquinone pharmacokinetics; AIDS, 784 warfarin; interactions, ciprofloxacin, PT effects, lack, N-Acetyl-p,1-penicillamine; antidotes; mercury poison- Anabolic agents; steroids; reclassification, controlled 136; nomograms, dosage, predictions, vs. comput- ing, pediatrics, 213 substances, 417 ers, 923; thromboembolism therapy, guidelines, Achlorhydria; glutamic acid hydrochloride; effects, Anabolic Steroids Act of 1990; laws; reclassification, 503 gastric pH, 866 controlled substances, 417 Anticonvulsants Acinetobacter species; resistance; ceftazidime, pneumo- Analgesics and antipyretics epilepsy; therapy, review, 335 nia, 49 acetaminophen; osteoarthritis therapy, geriatrics, ul- phenytoin; blood levels, effects, ultrafiltration and Acquired immunodeficiency syndrome cer history, 740; overdose, acetylcysteine therapy, freezing, 132; dosage calculations, black African aminoglycosides; pharmacokinetics, 784 765 and Indian children, 928 pentamidine; toxicity, pancreatitis, hemophilia, 56 alfentanil hydrochloride; DUE criteria, quality assur- phenytoin sodium; impaired metabolism, liver dis- therapy; Mycobacterium avium complex, review, 280; ance programs, 635; review, 581 eases, activated charcoal therapy, 711 research, AIDS conference, 809 codeine; allergies, alternative therapies, 658 valproate sodium; syrups, availability, vs. valproic Acyclovir; herpes zoster; and chickenpox, therapy, HIV fentanyl; FDA approvals, transdermal patches, pain acid emulsions, 382 infections, 301 therapy, 9; review, 581 valproic acid; emulsions, availability, vs. valproate Acyclovir sodium; herpes zoster; and chickenpox, ther- fentanyl citrate; DUE criteria, quality assurance pro- sodium syrup, 382 apy, HIV infections, 301 grams, 635 Antidepressants; tricyclic; panic disorders therapy, 893 Adrenergic agents, see Sympathomimetic agents ketorolac tromethamine; DUE criteria, 715 Antidiabetic agents; glyburide; pharmacokinetics, ef- Adsorbents; charcoal activated; therapy, impaired pain; postoperative, therapy, continuous epidural in- fects, age, 532 phenytoin metabolism, liver diseases, 711 fusions, 745; therapy, pediatrics, 667 Antidotes Adverse drug reactions report form, 71, 151, 233, 311, sufentanil; review, 581 acetylcysteine; acetaminophen overdose, 765 395, 479, 555, 641, 727, 801, 881, 959 sufentanil citrate; DUE criteria, quality assurance pro- digoxin immune Fab; toxicity, digoxin, 823 Adverse reactions, see Drugs, adverse reactions grams, 635 heavy-metal antagonists; poisoning, pediatrics, 213 Advertising Index, 80, 160, 246, 318, 404, 482, 558, 650, therapy; alternatives, codeine allergies, 658 Antiemetics 730, 806, 890, 976 Androgens; danazol; endometriosis therapy, 518 ondansetron hydrochloride; DUE criteria, quality as- Age; geriatrics; glyburide pharmacokinetics, 532 Anemia; epoetin; therapy, kidney failure, DUE criteria, surance programs, 471; pharmacology, review, 430; AIDS, see Acquired immunodeficiency syndrome 143, 303 prophylaxis, chemotherapy toxicity, FDA approv- Albumin human; nutrition; parenteral, supplements, Anesthetics, local als, 249 dosage predictions, pediatrics, 704 pain; postoperative, therapy, continuous epidural in- Antifungals Alcohols, cetyl; combination, colfosceril palmitate, ty- fusions, 745; therapy, pediatrics, 667 fluconazole; DUE criteria, quality assurance pro- loxapol; vs. beractant, therapeutic equivalency, 909 Angina pectoris; cardiac drugs; unstable, therapy, 825 grams, 222; pharmacology, review, 179 Alfentanil; pharmacology; clinical uses, review, 581 Angiotensin-converting enzyme inhibitors ketoconazole; Cushing’s syndrome therapy, 12 Alfentanil hydrochloride; use; review, criteria, quality heart failure; congestive, therapy, diastolic dysfunc- Anti-infective agents assurance programs, 635 tion, 850 Mycobacterium avium complex; combined therapy, Alglucerase; marketing; FDA approvals, 496 kidney diseases; therapy, 25 AIDS, review, 280 Allergies Anistreplase; comparison, alteplase, streptokinase; pentamidine; toxicity, pancreatitis, AIDS, 56 codeine; alternative analgesics, 658 myocardial infarction therapy, 486 pentamidine isethionate; infusions, adverse reac- latex; adverse reactions, FDA recommendations, 417 Antacids; use; evaluation, stress ulcer prophylaxis, cri- tions, facial numbness, 257 Alteplase; comparison, anistreplase, streptokinase; teria, 787 Anti-inflammatory agents myocardial infarction therapy, 486 Antianemia drugs; epoetin; DUE criteria, quality assur- aspirin; osteoarthritis therapy, geriatrics, ulcer his- Alzheimer’s disease; therapy; mechanism of action, re- ance programs, 143, 303 tory, 740 view, 447 Antiarrhythmic drugs, see Cardiac drugs etodolac; osteoarthritis therapy, FDA approvals, 416 980 Clinical Pharmacy Vol10 Dec 1991 Annual Index Index to Volume 10 The index to Volume 10 is composed of three parts: a subject Pharmacy, as well as selected letters and news reports. The subject index, an author index, and an advertising index. index also notes all regular columns and, under the respective The subject index is made up mainly of terms constructed by column headings, the titles of items in the “News,” “Therapy International Pharmaceutical Abstracts. The IPA index is an alpha- Consultation,” “Letters,” “Editorials,” and “Book Reviews” sec- betical, open-ended, controlled-vocabulary index that makes use tions. The subject index also contains, under the heading “Correc- of standardized headings. (The primary index terms for each ar- tion Notices,” the title and issue of publication of items for which ticle are listed routinely in Clinical Pharmacy as “index terms” after corrections were printed, as well as the page numbers on which abstracts.) IPA covers all authored papers and editorials in Clinical the corrections appear. Issue Pages Issue Pages January 1-80 July 483-566 February 81-160 August 567-650 March 161-246 September 651-730 April 247-318 October 731-806 May 319-404 November 807-890 June 405-482 December 891-990 Subject Index A Absorption Ambulatory care; hypertension; monitoring, devices, Antibiotics glyburide; effects, age, 532 assessment, 175 Mycobacterium avium complex; therapy, AIDS, review, triazolam; interactions, ranitidine, 539 Amikacin 280 Acetaminophen Mycobacterium avium complex; therapy, AIDS, review, imipenem; susceptibility, amikacin-resistant isolates, osteoarthritis; therapy, geriatrics, ulcer history, 740 280 in vitro, 544 pain; therapy, codeine allergies, 658 resistance; gram-negative bacteria, in vitro, 544 vancomycin; dosage guidelines, neonates, 129 poisoning; overdose, acetylcysteine therapy, 765 Amino acids; Alzheimer’s disease; therapy, mechanism vancomycin hydrochloride; blood levels, half-life, Acetazolamide; epilepsy; therapy, review, 335 of action, review, 447 hepatic and renal dysfunction, 297 Acetimidoquinone; metabolites; acetaminophen, toxic- Aminoglycosides Antibodies; monoclonal; radionuclides, immunother- ity, 765 amikacin; Mycobacterium avium complex, AIDS, 280; apy, neoplasms, 359 Acetylcholinesterase inhibitors; Alzheimer’s disease; resistance, gram-negative bacteria, in vitro, 544 Anticoagulants therapy, mechanism of action, review, 447 gentamicin; dosage predictions, pharmacokinetics, heparin; i.v. infusion sites, toxicity, 630; thromboem- Acetylcysteine; therapy; acetaminophen overdose, 765 methodology, 706; renal function estimation, 931; bolism therapy, guidelines, 503 N-Acetylimidoquinone, see Acetimidoquinone pharmacokinetics; AIDS, 784 warfarin; interactions, ciprofloxacin, PT effects, lack, N-Acetyl-p,1-penicillamine; antidotes; mercury poison- Anabolic agents; steroids; reclassification, controlled 136; nomograms, dosage, predictions, vs. comput- ing, pediatrics, 213 substances, 417 ers, 923; thromboembolism therapy, guidelines, Achlorhydria; glutamic acid hydrochloride; effects, Anabolic Steroids Act of 1990; laws; reclassification, 503 gastric pH, 866 controlled substances, 417 Anticonvulsants Acinetobacter species; resistance; ceftazidime, pneumo- Analgesics and antipyretics epilepsy; therapy, review, 335 nia, 49 acetaminophen; osteoarthritis therapy, geriatrics, ul- phenytoin; blood levels, effects, ultrafiltration and Acquired immunodeficiency syndrome cer history, 740; overdose, acetylcysteine therapy, freezing, 132; dosage calculations, black African aminoglycosides; pharmacokinetics, 784 765 and Indian children, 928 pentamidine; toxicity, pancreatitis, hemophilia, 56 alfentanil hydrochloride; DUE criteria, quality assur- phenytoin sodium; impaired metabolism, liver dis- therapy; Mycobacterium avium complex, review, 280; ance programs, 635; review, 581 eases, activated charcoal therapy, 711 research, AIDS conference, 809 codeine; allergies, alternative therapies, 658 valproate sodium; syrups, availability, vs. valproic Acyclovir; herpes zoster; and chickenpox, therapy, HIV fentanyl; FDA approvals, transdermal patches, pain acid emulsions, 382 infections, 301 therapy, 9; review, 581 valproic acid; emulsions, availability, vs. valproate Acyclovir sodium; herpes zoster; and chickenpox, ther- fentanyl citrate; DUE criteria, quality assurance pro- sodium syrup, 382 apy, HIV infections, 301 grams, 635 Antidepressants; tricyclic; panic disorders therapy, 893 Adrenergic agents, see Sympathomimetic agents ketorolac tromethamine; DUE criteria, 715 Antidiabetic agents; glyburide; pharmacokinetics, ef- Adsorbents; charcoal activated; therapy, impaired pain; postoperative, therapy, continuous epidural in- fects, age, 532 phenytoin metabolism, liver diseases, 711 fusions, 745; therapy, pediatrics, 667 Antidotes Adverse drug reactions report form, 71, 151, 233, 311, sufentanil; review, 581 acetylcysteine; acetaminophen overdose, 765 395, 479, 555, 641, 727, 801, 881, 959 sufentanil citrate; DUE criteria, quality assurance pro- digoxin immune Fab; toxicity, digoxin, 823 Adverse reactions, see Drugs, adverse reactions grams, 635 heavy-metal antagonists; poisoning, pediatrics, 213 Advertising Index, 80, 160, 246, 318, 404, 482, 558, 650, therapy; alternatives, codeine allergies, 658 Antiemetics 730, 806, 890, 976 Androgens; danazol; endometriosis therapy, 518 ondansetron hydrochloride; DUE criteria, quality as- Age; geriatrics; glyburide pharmacokinetics, 532 Anemia; epoetin; therapy, kidney failure, DUE criteria, surance programs, 471; pharmacology, review, 430; AIDS, see Acquired immunodeficiency syndrome 143, 303 prophylaxis, chemotherapy toxicity, FDA approv- Albumin human; nutrition; parenteral, supplements, Anesthetics, local als, 249 dosage predictions, pediatrics, 704 pain; postoperative, therapy, continuous epidural in- Antifungals Alcohols, cetyl; combination, colfosceril palmitate, ty- fusions, 745; therapy, pediatrics, 667 fluconazole; DUE criteria, quality assurance pro- loxapol; vs. beractant, therapeutic equivalency, 909 Angina pectoris; cardiac drugs; unstable, therapy, 825 grams, 222; pharmacology, review, 179 Alfentanil; pharmacology; clinical uses, review, 581 Angiotensin-converting enzyme inhibitors ketoconazole; Cushing’s syndrome therapy, 12 Alfentanil hydrochloride; use; review, criteria, quality heart failure; congestive, therapy, diastolic dysfunc- Anti-infective agents assurance programs, 635 tion, 850 Mycobacterium avium complex; combined therapy, Alglucerase; marketing; FDA approvals, 496 kidney diseases; therapy, 25 AIDS, review, 280 Allergies Anistreplase; comparison, alteplase, streptokinase; pentamidine; toxicity, pancreatitis, AIDS, 56 codeine; alternative analgesics, 658 myocardial infarction therapy, 486 pentamidine isethionate; infusions, adverse reac- latex; adverse reactions, FDA recommendations, 417 Antacids; use; evaluation, stress ulcer prophylaxis, cri- tions, facial numbness, 257 Alteplase; comparison, anistreplase, streptokinase; teria, 787 Anti-inflammatory agents myocardial infarction therapy, 486 Antianemia drugs; epoetin; DUE criteria, quality assur- aspirin; osteoarthritis therapy, geriatrics, ulcer his- Alzheimer’s disease; therapy; mechanism of action, re- ance programs, 143, 303 tory, 740 view, 447 Antiarrhythmic drugs, see Cardiac drugs etodolac; osteoarthritis therapy, FDA approvals, 416 980 Clinical Pharmacy Vol10 Dec 1991 Annual Index ibuprofen; interactions, misoprostol, ranitidine, lack, acetaminophen; overdose, monitoring, 765 Carisoprodol; muscle cramp; therapy, nocturnal leg 870; osteoarthritis therapy, geriatrics, ulcer history, albumin human; dosage predictions, pediatrics, 704 cramps, 427 740 antiarrhythmic agents; therapy, monitoring, 211 Caucasians; psychotherapeutic agents; pharmacokinet- nonsteroidal; pain therapy, codeine allergies, 658 benzodiazepines; Asians vs. Caucasians, 467 ics, vs. Asians, 467 salsalate; osteoarthritis therapy, geriatrics, ulcer his- cardiac drugs; ventricular arrhythmia therapy, 195 Ceftazidime tory, 740 digoxin; toxicity, digoxin immune Fab retreatment, comparison, ciprofloxacin lactate; therapy, noso- scleroderma; systemic, therapy, 14 immunogenicity, 823 comial pneumonia and urinary tract infections, 49 Antilipemic agents gentamicin; dosage, predictions, pharmacokinetics, effects; amikacin-resistant isolates, in vitro, 544 cholestyramine resin; palatability, oral formulations, 706 Cephalosporins; ceftazidime; susceptibility, amikacin- vehicles, 138 glyburide; pharmacokinetics, effects, age, 532 resistant isolates, in vitro, 544; vs. ciprofloxacin, colestipol hydrochloride; palatability, oral formula- lead; succimer therapy, FDA restrictions, 942 pneumonia and urinary tract infections therapy, 49 tions, vehicles, 138 lithium; pharmacokinetics, methodology, models, Charcoal activated; therapy; impaired phenytoin excre- hyperlipidemia; therapy, protocols, 943 376 tion, liver diseases, 711 Antimanic agents mercury; poisoning, pediatrics, 213 Chickenpox; acyclovir; therapy, prophylaxis, HIV in- lithium; neutropenia therapy, HIV infections, review, phenytoin; dosage calculations, black African and fections, 301 268 Indian children, 928; effects, ultrafiltration and Chloral hydrate; interactions; furosemide, pediatrics, lithium carbonate; pharmacokinetics, methodology, freezing, 132; high, impaired metabolism, 711 385 models, 376 recainam hydrochloride; pharmacokinetics, com- Cholestyramine, see Cholestyramine resin Antineoplastic agents puter programs, MS-DOS vs. Macintosh, 206 Cholestyramine resin fludarabine phosphate; FDA approvals, 496 triazolam; interactions, ranitidine, 539 hyperlipidemia; therapy, protocols, 943 fluorouracil and levamisole; colonic neoplasms, com- valproic acid; availability, stability, emulsions, 382 palatability; oral formulations, vehicles, preferences, bined therapy, 95 vancomycin; dosage guidelines, neonates, 129; half- 138 interleukin 2; renal cell carcinoma, single agent ther- life, hepatic and renal dysfunction, 297 Choline; Alzheimer’s disease; therapy, mechanism of apy, FDA denial, 141; therapy, review, 110 Bloodletting; hemochromatosis; therapy, 775 action, review, 447 levamisole; colorectal neoplasms therapy, review, 95 Book Reviews, 80, 159, 239, 316, 649, 729, 305, 885, 970 Ciprofloxacin; effects; amikacin-resistant isolates, in toxicity; nausea and vomiting, ondansetron prophy- Biopharmaceutics and Clinical Pharmacokinetics, Fourth vitro, 544 laxis, 430; nausea and vomiting, ondansetron ther- Edition, 649 Ciprofloxacin hydrochloride; interactions; warfarin, PT apy, DUE criteria, 471; neutropenia, filgrastim pro- Cancer Chemotherapy by Infusion, Second Edition, 239 effects, lack, 136 phylaxis, DUE criteria, 950; neutropenia, filgrastim Clinical Pharmacology of Psychotherapeutic Drugs, Third Ciprofloxacin lactate; comparison, ceftazidime; ther- prophylaxis, FDA approvals, 321; ondansetron pro- Edition, 159 apy, nosocomial pneumonia and urinary tract infec- phylaxis, FDA approvals, 249 Diseases of the Nose, Throat, Ear, Head, and Neck, Four- tions, 49 Antithyroid drugs; propylthiouracil; hyperthyroidism teenth Edition, 729 Classification; steroids; anabolic, controlled sub- therapy, mercury poisoning, 742 Drug Interactions & Updates, 1991, 805 stances, 417 Antivirals Drug Safety in Pregnancy, 650 Clearance, see Excretion acyclovir; chickenpox, herpes zoster therapy, HIV in- Drugs in Pregnancy and Lactation, Third Edition, 316 Clindamycin phosphate; concomitant therapy, 931 fections, 301 Field Drug Reference for Emergency Care Providers, 80 Clinical Pharmacy zidovudine; toxicity, neutropenia, HIV infections, Goodman and Gilman's The Pharmacological Basis of acknowledgment to reviewers—October 1, 1990, to review, 268 Therapeutics, 8th edition, 317 September 30, 1991, 946 Anxiolytics, sedatives and hypnotics Handbook of Drug Therapy in Liver and Kidney Disease, instructions for submitting computer disks with re- chloral hydrate; interactions, furosemide, pediatrics, 885 vised manuscripts, 62 385 Handbook of Psychiatric Emergencies, 730 procedure for submission of manuscripts to journals lorazepam; dosage, pediatrics, 625 Infections in Intravenous Drug Abusers, 805 published by the American Society of Hospital midazolam hydrochloride; DUE criteria, quality as- Manual of Clinical Microbiology, Fifth Edition, 885 Pharmacists6, 0 surance programs, 388 Patient Compliance in Medical Practice and Clinical Clinical studies triazolam; interactions, ranitidine, pharmacokinetics, Trials, 970 meta-analysis; health data, applications anc prob- 539 Pharmacological Treatment of Endocrinopathies: Bone Dis- lems, 4 Arecoline; Alzheimer’s disease; therapy, mechanism of ease, Kidney Stones and Related Disorders, 890 ondansetron hydrochloride; prophylaxis, antineo- action, review, 447 Poisoning and Drug Overdose, 243 plastics toxicity, 430 Arrhythmia Regional Antineoplastic Drug Delivery in the Manage- Codeine; allergies; alternative analgesics, 658 antiarrhythmic agents; therapy, blood levels, moni- ment of Malignant Disease, 976 Colestipol; hyperlipidemia; therapy, protocols, 943 toring, 211 Books Received, 246, 318, 482, 650, 806, 890, 976 Colestipol hydrochloride; palatability; oral formula- cardiac drugs; ventricular, therapy, review, 195 Botulinum toxin type A; dystonia; therapy, 88 tions, vehicles, preferences, 138 encainide hydrochloride; toxicity, product withdraw- Bristol Laboratories; encainide hydrochloride; product Colfosceril palmitate; combination, alcohols, cetyl, ty- al, 897 withdrawal, toxicity, 897 loxapol; vs. beractant, therapeutic equivalency, 909 moricizine; therapy, DUE criteria, 873 Bromocriptine; restless legs; therapy, nocturnal, 427 Colonic neoplasms therapy; ventricular, pharmacists, monitoring, 210 Bronchodilators; cromolyn sodium; asthma therapy, fluorouracil and levamisole; combined therapy, re- Asians; psychotherapeutic agents; pharmacokinetics, pediatrics, 685 view, 95 vs. Caucasians, 467 levamisole and fluorouracil; combined therapy, re- Aspirin view, 95 alone and with flurbiprofen; effects, platelet aggrega- Cc Colony-stimulating factors tion, 935 filgrastim; DUE criteria, 950 and propoxyphene; pain therapy, codeine allergies, neutropenia; therapy, HIV infections, review, 268 658 Calcium antagonists sargramostim; DUE criteria, 947 and thrombolytic agents; myocardial infarction ther- concomitant therapy, 630 Colorectal neoplasms apy, 486 heart failure; congestive, therapy, diastolic dysfunc- interleukin 2; therapy, 110 myocardial infarction; prophylaxis, angina pectoris, tion, 850 levamisole; therapy, review, 95 825 proteinuria; therapy, diabetic nephropathies, 862 Combined therapy osteoarthritis; therapy, geriatrics, ulcer history, 740 Calcium regulators; gallium nitrate; hypercalcemia aspirin and thrombolytic agents; myocardial infarc- Asthma; therapy; pediatrics, 685 therapy, FDA approvals, 573 tion, effects, mortality, 486 Availability, drugs, see Drugs, availability Calculations; phenytoin; dosage, black African and In- fluorouracil and levamisole; colonic neoplasms, re- dian children, 928 view, 95 Cancer, see Antineoplastic agents levamisole and fluorouracil; colonic neoplasms, re- Cancer drugs, see Antineoplastic agents view, 95 Candidiasis; fluconazole; therapy, DUE criteria, 222 thrombolytic agents and aspirin; myocardial infarc- Captopril tion, effects, mortality, 486 Barbiturates; delirium; therapy, intensive-care units, concomitant therapy, 500 Commentary, 943 456 kidney diseases; therapy, 25 Compliance; patients; deferoxamine therapy, hemo- Benazepril hydrochloride; marketing; FDA approvals, Carbamazepine chromatosis, 775 739 epilepsy; therapy, review, 335 Computers; programs; MS-DOS vs. Macintosh, re- Benzodiazepines restless legs; therapy, nocturnal, 427 cainam pharmacokinetics, 206; NONMEM, lithium alone and with haloperidol; delirium therapy, inten- Carcinoma; interleukin 2; renal cell, single agent ther- pharmacokinetics, 376; warfarin dosage, predictions, sive-care units, 456 apy, FDA denial, 141; renal cell, therapy, 110 vs. nomogram, 923 epilepsy; therapy, review, 335 Cardiac drugs Contraceptives, oral; endometriosis; therapy, 518 panic disorders; therapy, 893 angina pectoris; unstable, therapy, 825 Contraindications pharmacokinetics; Asians vs. Caucasians, 467 antiarrhythmic agents; therapy, blood levels, moni- botulinum toxin type A, 88 Beractant; comparison, alcohols, cetyl, combination, toring, 211; therapy, monitoring, pharmacists, 210 drugs; lactation, 594 colfosceril palmitate, tyloxapol; therapeutic equiva- arrhythmia; ventricular, therapy, review, 195 Controlled substances; steroids; anabolic, reclassifica- lency, 909 digoxin; toxicity, digoxin immune Fab retreatment, tion, 417 Beverages; vehicles; cholestyramine, colestipol admin- immunogenicity, 823 Copper Cu 67; radionuclides; monoclonal antibodies, istration, palatability, 138 encainide hydrochloride; product withdrawal, toxic- neoplasms, 359 Bioavailability, see Drugs, availability ity, 897 Correction Notices, 261, 429, 501, 824, 913 Blood derivatives; albumin human; dosage predictions, moricizine; arrhythmia therapy, DUE criteria, 873 Attention-deficit hyperactivity disorder (Aug 1990, parenteral supplements, pediatrics, 704 recainam hydrochloride; pharmacokinetics, com- Therapy Review), 261 Blood levels puter programs, MS-DOS vs. Macintosh, 206 Criteria for use of ketorolac tromethamine in adult Vol 10 Dec 1991 Clinical Pharmacy 981 Annual Index inpatients and outpatients (Sep 1991, DUE Crite- etodolac, 416 lack, 935 ria), 913 fentanyl; transdermal patches, pain therapy, 9 furosemide and chloral hydrate; pediatrics, 385 Current issues in the treatment of epilepsy (May 1991, fentanyl citrate; DUE criteria, 635 ibuprofen and misoprostol or ranitidine hydrochlo- Therapy Review), 501 filgrastim, 321; neutropenia prophylaxis, chemother- ride; lack, 870 Hypoprothrombinemic effect of warfarin not influ- apy, DUE criteria, 950 misoprostol and ibuprofen; lack, 870 enced by ciprofloxacin (Feb 1991, Research Notes), fluconazole; DUE criteria, 222 ranitidine hydrochloride and ibuprofen; lack, 870 429 fludarabine phosphate, 496 ranitidine hydrochloride and triazolam; pharmacoki- Intravenous quinidine recommended for severe Plas- gallium nitrate, 573 netics, 539 modium falciparum malaria; injectable quinine dis- gastrointestinal drugs; stress ulcer prophylaxis, DUE triazolam and ranitidine hydrochloride; pharmacoki- continued by CDC Drug Service (Sep 1991, News), criteria, 787 netics, 539 913 gentamicin; predictions, pharmacokinetics, method- warfarin and ciprofloxacin hydrochloride; PT effects, Management of postoperative pain by continuous ology, 706 lack, 136 epidural infusion of analgesics (Oct 1991, Therapy heparin; thromboembolism therapy, guidelines, 503 Drug interactions therapy; aspirin and flurbiprofen; ef- Review), 824 hetastarch; DUE criteria, 549 fects, platelet aggregation, lack, 935 Olsalazine approved for use in ulcerative colitis (Dec interleukin 2; neoplasms therapy, 110 Drug Reaction Alerts, 74, 154, 235, 313, 397, 478, 558, 1990, News), 261 isradipine, 573 644, 726, 803, 880, 966 Costs ketorolac tromethamine; DUE criteria, 715 Drugs, adverse reactions deferoxamine mesylate; hemochromatosis therapy, levamisole; colorectal neoplasms therapy, 95 codeine; allergies, alternative analgesics, 658 775 lorazepam; sedation, amnesia, pediatrics, 625 latex; allergies, FDA recommendations, 417 filgrastim; prophylaxis, neutropenia, FDA approvals, midazolam hydrochloride; DUE criteria, 388 pentamidine isethionate; facial numbness, infusions, 321 misoprostol; DUE criteria, 307 257 interleukin 2; renal cell carcinoma, single agent ther- moricizine; arrhythmia therapy, DUE criteria, 873 vaccines; Vaccine Adverse Event Reporting System, 9 apy, FDA denial, 141 ondansetron hydrochioride, 249; DUE criteria, 471; Drugs, availability pulmonary surfactants; respiratory distress syn- review, 430 triazolam; interactions, ranitidine, 539 drome therapy, 909 overdose; acetaminophen, acetylcysteine therapy, 765 valproate sodium; syrups, vs. valproic acid emul- sargramostim, 411 phenytoin; calculations, black African and Indian sions, 382 thrombolytic agents; myocardial infarction therapy, children, 928 valproic acid; emulsions, vs. valproate sodium syrup, 486 psychotherapeutic agents; Asians vs. Caucasians, 467 382 CP Continuing Education, 68, 147, 228, 309, 392, 474, pulmonary surfactants; respiratory distress syn- Drugs, body distribution 552, 638, 718, 792, 876, 953 drome therapy, 909 aminoglycosides; AIDS, 784 Creatinine; clearance; gentamicin excretion, renal func- radiopharmaceuticals; monoclonal antibodies, neo- glyburide; effects, age, 532 tion estimation, 931; predictions, lithium pharma- plasms, 359 lithium; pharmacokinetics, methodology, models, cokinetics, models, 376 ramipril, 573 376 Cromolyn sodium; asthma; therapy, pediatrics, 685 sargramostim, 411; DUE criteria, 947 Drugs, clinical effectiveness Current Literature, 74, 154, 235, 313, 397, 478, 558, 644, skeletal muscle relaxants; mechanically ventilated antiarrhythmic agents; therapy, blood leveis, moni- 726, 803, 880, 966 patients, 32 toring, 211 Cushing’s syndrome; ketoconazole; therapy, mecha- succimer; lead poisoning, therapy, 914 drugs, nonprescription; lack, product withdrawal, nism of action, 12 sufentanil citrate; DUE criteria, 635 FDA list, 88 Cytokines; Mycobacterium avium complex; therapy, terbutaline sulfate; preterm labor, home infusion meta-analysis; methodology, applications and prob- AIDS, review, 280 therapy, 292 lems, 4 Cytotoxic agents, see Antineoplastic agents vancomycin; guidelines, neonates, 129 thrombolytic agents; myocardial infarction therapy, vancomycin hydrochloride; hepatic and renal dys- 486 function, 297 Drugs, nonprescription; product withdrawal; ingredi- D warfarin; predictions, nomograms vs. computers, ents, FDA list, 88 923; thromboembolism therapy, guidelines, 503 Drug use Dosage forms evaluation; filgrastim, neutropenia prophylaxis, crite- Danazol; endometriosis; therapy, 518 etodolac, 416 ria, 950; gastrointestinal drugs, stress ulcer prophy- Deferoxamine mesylate; hemochromatosis; therapy, filgrastim, 321 laxis, criteria, 787; ketorolac, criteria, 715; mori- 775 ondansetron hydrochloride, 249 cizine, arrhythmia therapy, criteria, 873; sargra- Delirium; therapy; review, intensive-care units, 456 sargramostim, 411 mostim, criteria, 947 Desmopressin acetate; dosage; high, mechanism of ac- Dosage schedules review; alfentanil, fentanyl, sufentanil, criteria, qual- tion, antidiuretic effects, 912 acetylcysteine; therapy, acetaminophen overdose, 765 ity assurance programs, 635; enalapril, criteria, Devices analgesics; continuous epidural infusions, postopera- quality assurance programs, 63; epoetin, criteria, blood pressure; ambulatory care, monitoring, assess- tive pain, 745 quality assurance programs, 143, 303; fluconazole, ment, 175 anticonvulsants; epilepsy therapy, long term, 335 criteria, quality assurance programs, 222; heta- infusion pumps; terbutaline, preterm labor, home aspirin and ‘lurbiprofen; platelet aggregation effects, starch, criteria, quality assurance programs, 549; therapy, 292 935 midazolam, criteria, quality assurance programs, medical; latex, adverse reactions, FDA recommenda- flurbiprofen and aspirin; platelet aggregation effects, 388; misoprostol, criteria, quality assurance pro- tions, 417 935 grams, 307; ondansetron, criteria, quality assurance Diabetes mellitus; calcium antagonists; diabetic neph- interleukin 2; renal cell carcinoma, single agent ther- programs, 471 ropathies, proteinuria therapy, 862 apy, FDA denial, 141 DUE Criteria, 63, 143, 222, 303, 388, 471, 549, 635, 715, Diabetic nephropathies; calcium antagonists; protein- Doxazosin mesylate; hypertension; therapy, FDA ap- 787, 873, 947 uria therapy, diabetes mellitus, 862 provals, 9 enalapril maleate, 63 Digoxin; toxicity; therapy, digoxin immune Fab retreat- Drug administration epoetin, 143, 303 ment, immunogenicity, 823 cholestyramine resin; beverages, palatability, 138 fentanyl citrate, sufentanil citrate, and alfentanil hy- Digoxin immune Fab; therapy; immunogenicity, re- colestipol hydrochloride; beverages, palatability, 138 drochloride, 635 treatment, 823 self-medication; terbutaline infusion, preterm labor filgrastim, 950 Diltiazem therapy, 292 fluconazole, 222 angina pectoris; unstable, therapy, 825 succimer; lead poisoning, therapy, 914 hetastarch, 549 proteinuria; therapy, diabetic nephropathies, 862 thrombolytic agents; comparisons, myocardial infarc- ketorolac tromethamine, 715 Dimercaprol; antidotes; mercury poisoning, pediatrics, tion therapy, 486 midazolam hydrochloride, 388 213 Drug administration rate; injections; continuous vs. in- misoprostol, 307 Diuretics termittent infusion, toxicity, 630 moricizine, 873 and doxazosin mesylate; hypertension therapy, 9 Drug administration routes ondansetron hydrochloride, 471 furosemide; interactions, chloral hydrate, pediatrics, asthma; acute vs. prophylactic therapy, pediatrics, sargramostim, 947 385 685 stress ulcer prophylaxis in intensive-care patients, 787 heart failure; congestive, therapy, diastolic dysfunc- deferoxamine mesylate; s.c., i.v., hemochromatosis Dystonia; botulinum toxin type A; therapy, 88 tion, 850 therapy, 775 Dosage epidural; analgesics, continuous epidural infusions, acyclovir; chickenpox, herpes zoster therapy, HIV in- postoperative pain, 745 E fections, 301 pentamidine isethionate; infusions, adverse reac- albumin human; predictions, equations, parenteral tions, facial numbness, 257 supplements, pediatrics, 704 terbutaline sulfate; subcutaneous infusion, preterm Edetate calcium disodium; therapy; mercury poison- alfentanil hydrochloride; DUE criteria, 635 labor therapy, 292 ing, 742 analgesics; pain therapy, pediatrics, 667 triazolam; oral vs. i.v., interactions, ranitidine, phar- Editorials, 141, 210, 942 benazepril hydrochloride, 739 macokinetics, 539 Antiarrhythmic monitoring: misplaced emphasis, 211 charcoal activated; multiple dose therapy, phenytoin Drug administration sites; intravenous; toxicity, extra- Recombinant interleukin-2 and the quest for FDA toxicity, liver diseases, 711 vasation, phlebitis, 630 approval, 141 desmopressin acetate; high, mechanism of action, an- Drug interactions Succimer: controversial issues involving the release tidiuretic effects, 912 chloral hydrate and furosemide; pediatrics, 385 of a new product, 942 digoxin immune Fab, 823 ciprofloxacin hydrochloride and warfarin; PT effects, Trials and tribulations of evaluating ventricular doxazosin mesylate; hypertension, therapy, 9 lack, 136 arrhythmias, 210 enalapril maleate; DUE criteria, 63 fluconazole; review, 179 Education epoetin; DUE criteria, 143, 303 flurbiprofen and aspirin; effects, platelet aggregation, acquired immunodeficiency syndrome; therapy, re- 982 Clinical Pharmacy Vol 10 Dec 1991 Annual Index search, AIDS conference, 809 5-FU, see Fluorouracil Hypercalcemia; gallium nitrate; therapy, cancer-re- panic disorders; awareness, therapy, 893 Furosemide; interactions; chloral hydrate, pediatrics, lated, FDA approvals, 573 Elimination, see Metabolism 385 Hyperlipidemia; therapy; protocols, National Choles- Emulsions; valproic acid; stability, availability, vs. val- terol Education Program, 943 proate sodium syrup, 382 G Hypertension Enalapril maleate benazepril hydrochloride; therapy, FDA approvals, kidney diseases; therapy, 25 739 use; review, criteria, quality assurance programs, 63 Gallium nitrate; marketing; FDA approvals, 573 calcium antagonists; therapy, diabetic nephropathies, Encainide hydrochloride; product withdrawal; toxic- Gastrointestinal drugs 862 ity, 897 glutamic acid hydrochloride; effects, gastric pH, 866 doxazosin mesylate; therapy, FDA approvals, 9 Endometriosis; therapy, 518 histamine H, antagonists; use, evaluation, stress ulcer enalapril maleate; DUE criteria, 63 Enterobacter cloacae; resistance; ceftazidime, pneumo- prophylaxis, criteria, 787 isradipine; therapy, FDA approvals, 573 nia, 49 misoprostol; DUE criteria, quality assurance pro- labetalol hydrochloride; therapy, pediatrics, 500 Enzymes; alglucerase; replacement therapy, Gaucher's grams, 307; interactions, ibuprofen, lack, 870 ramipril; therapy, FDA approvals, 573 disease, FDA approvals, 496 ranitidine; peptic ulcers, prophylaxis, osteoarthritis, therapy; ambulatory care, monitoring, assessment, Epilepsy; therapy; review, 335 geriatrics, 740 175 Epoetin; use; review, criteria, quality assurance pro- ranitidine hydrochloride; interactions, ibuprofen, Hyperthyroidism; mercury; toxicity, poisoning, 742 grams, 143, 303 lack, 870; interactions, triazolam, pharmacokinet- Hypotensive agents Equations ics, 539 benazepril hydrochloride; FDA approvals, 739 albumin human; dosage, predictions, pediatrics, 704 scleroderma; systemic, therapy, 14 doxazosin mesylate; therapy, FDA approvals, 9 phenytoin; dosage, pediatrics, pharmacogenetics, 928 sucralfate; stress ulcer prophylaxis, DUE criteria, 787 enalapril maleate; DUE criteria, quality assurance Equivalency Gaucher's disease; alglucerase; therapy, FDA approv- programs, 63 valproate sodium; syrups, availability, vs. valproic als, 496 isradipine; FDA approvals, 573 acid emulsions, 382 Gentamicin labetalol hydrochloride; therapy, pediatrics, 500 valproic acid; emulsions, availability, vs. valproate dosage; predictions, pharmacokinetics, methodology, ramipril; FDA approvals, 573 sodium syrup, 382 706 Equivalency, generic; thioridazine hydrochloride; excretion; renal function estimation, 931 brands, comparison, efficacy, quality of life, 938 Geriatrics; osteoarthritis; therapy, ulcer history, 740 Equivalency, therapeutic; pulmonary surfactants; com- Globulin immune; neutropenia; therapy, HIV infec- parison, respiratory distress syndrome therapy, 909 tions, review, 268 EEtthhangoiescnu txsgi,rm oipudhpesa;;r maeHcpiioslgpeeapnnseiytc;i ctAshm,ee rra4ip6cy7a, n sr;e vipeswy,c h3o3t5h erapeutic GGGlloysubetruaermliiidcne ;a caipgdho anirhsmytadscr;oo kcihnnlaeoftarriiecdlsei;;n ; eeffeffneeccdttossm;, etgargaesi,to rsi5ic3s 2 p Ht,h e8r6a6p y, IIabtuirnpotrgeoerfanecitnci odnis;s eamsiesso,p rsoeset oDlr,u grsa,n itaiddvienres,e larceka,c t8i7o0n s EEtxoctdrhoeeltraiacop;ny , m4a16r keting; FDA approvals, osteoarthritis Gui5d1e8l ines, treatment, see Protocols Imoispteenoaermt;hr iteiffse;c tst;h eraampiyk,a cigner-iraetsriiscst,a ntul ceirs olhaitsetso,r yi,n 7v4i0t ro, 544 abmeinnzoogdliyaczoespiidneess;; AcIlDeSa,ra n7c8e4, Asians vs. Caucasians, H Immunogenicity; digoxin immune Fab; retreatment, 467 digoxin toxicity, 823 drugs; lactation, review, 594 Immunosuppressive agents; scleroderma; systemic, ggleynbtuarmiidcei;n ; efrfeecntasl, faugnec,t i5o3n2 estimation, 931 Halafm-ilinfoeg lycosides; AIDS, 784 Imtmhuenraoptyh,e r1a4 py lithium; clearance, methodology, models, 376 vancomycin; blood levels, hepatic and renal dysfunc- colony-stimulating factors; neutropenia, HIV infec- phecnhyartcooianl stohdeiruampy;, i7m1p1a ired, liver diseases, activated Halopteiorni,d o2l9;7 alone and with benzodiazepines; delirium filtgiroansst,i mr;e vineewu,t r2o6p8e nia prophylaxis, chemotherapy, vancomycin; hepatic and renal dysfunction, 297 therapy, intensive-care units, 456 DUE criteria, 950; prophylaxis, neutropenia, FDA Extravasation; injections; i.v. infusion sites, toxicity, 630 Heasilst, h4- benefit programs; reimbursement; meta-analy- gloabpuplrionv alism,m u3n21e ; neutropenia, HIV infections, re- F Heatlhtehr apcya,r e;2 92h ome; terbutaline infusion, preterm labor intveirelwe,u ki26n8 2; neoplasms therapy, 110 Health professions; latex; medical devices, allergies, rad3i5o9n uclides; monoclonal antibodies, neoplasms, FDA recommendations, 417 sargramostim; DUE criteria, 947; FDA approvals, 411 FFeennppttahaatanncryyhmllea sc cotiltroraagntyse;;d erucsmleai;ln i;cr aelvp iaueiswne, s ,t hcreriretavepriyiea,w, , FquD5a8A1l itayp parsosvuarlasn,c e9 HedaN-evafaycte reritmcoyesxl,ta- apm2l,i1 .3na- enp etnaigmceoisnlyillsaatmtsie n;e ; hemmeorcchurryo maptooissiosni ngt,h erpaepdyi,- IInnfc4eo3cm0tp iaotnisb;i litthieersa;p y;o nodpapnosrettunriosnt ich,y drroescehalrocrhi,d e;A IDrSe viceown,- Filpgrroagsrtaimms , 635 dim7e7r5 caprol; mercury poisoning, pediatrics, 213 Inffuesreinocne , de8v0i9c es, see Devices; infusion pumps Filau1tspe3erp2t;sr h ;o eevrvuaaallptlsyru;a,a; t i3pFo2rn1Do ,Ad ,u ncetupstr,ro poehpfyeflneacitxasi ,s p,pr hopenhneyyulttaorxioinpse ,n bilacor,io tde rcihla,ee vme9ol5s-0, epsdeuenciaticnpacigyt,im,e le 7lr84a;c32m a9 il ncFeiD;u Am hdeaippsapotrdooliveuanmlts;i, c utlhcaeorrn atpryod,ve egrmesenireecrs,au triyo9 4n2 p;o itslhoeenar-d- Injabfenoucatrttliouigvsloeeenis msinpi cuadsim;en ;, tco7oxi4nin5tnt i enrtauycoptueis o nAs;e, p diydcshutlrooarnlai la i nhftyuhdseirroaantpsey,,, p8po8esd tioatpreircas-, FFilluptcrhoaatnriamoznao;c loeul lotrgay;; mertehvioedws,, 1p7h9e nytoin blood levels, 132 tzirnipceo;n tiisnoehn;ei pnahgte,op laettnhoetlrieacnputyli,ac ru l9a14rd edgeegneenreartaitoino, n tmhaeirnatpey,n an8c39e gal3all8si5,u m5 73n itrate; hypercalcemia therapy, FDA approv- FFFllluuubu4aosrd9igreb6nag;oi err updearrr gbaeoaictvftnihieileeeno; wr;n ,a , ppa ychan,9rlod i3o st59nep 5erlh i eaav,taa enmq;diu s aollwmieita;tyr h k eactosailssopnunigrri;aic nn c;e nF eDeopfApfr elocagtsasr,mpa spm,rspo l,va catole2lms2e-,2t HHHeeempmm5in6oaoyj protcehhichceiantrrirl ooadimnpiasyaa;;,t l o i8s.pv3iie.9 nsn fit;ana rfmcuttisihdioeionrnn;ae p;ys pi,tr etoso7p,x7 hi5yct liotaxyix,ci ist,py ,a nca6rn3eg0ai tniati s,p ecAtoIrDiSs,, Intiptaeneperrtpntllbrritaueaoobatnuvvomsakear,ilin l idnostnfi u;heasn ce 2;eir ra aselpu ntlyaonif,lxusa i temce2ctibe;9htln 2yile,o snscauesatbx,retcc ;rui a2tnv5aoa7imns naeaf,otu iusoissno i,nns gi,lnp efh ulsaaeibgdioevtnnei,trs s,e tp h6re3er0tra eeparycm,- Fooadp praonvda lsD;r uga lgAldumcienriasster atmiaornk et(iUn.gS.,) 496; benazepril th8r2o5m boembolism; therapy, guidelines, 503 neoFpDlAa smdsen;i alt,h er1a4p1 y, review, 110 marketing, 739; doxazosin, hypertension therapy, Hepatolenticular degeneration; heavy metal antago- Iodnienoep laIs m1s2,5 ; 35r9a dionuclides; monoclonal antibodies, 9pk;ea tteicnthgoe,ds o, l3am2ca1 ;r kmeaftrlikunedgta,ir nagpbai,in ne 41t6hm;ea rrafkpeeynt,ti ann9gy;,l ,f il4gt9r6ra;as ntsigdmae lrlmmaiarul-m Hernfiepscettssi;o ntzsoh,s etr3ea0rp1;y , ac8y3c9l ovir; therapy, prophylaxis, HIV in- IIosrdnaiednoiepp lianIes ;m 1s3,m1 a;r 3k5er9ta idniogn;u cFliDdAe s;a pprmoovnaolcsl,o n5a7l3 antibodies, marketing, 573; isradipine, ramipril, marketing, Hetastarch; use; review, criteria, quality assurance pro- 573; ondansetron, 249; sargramostim marketing, grams, 549 411; succimer marketing, controversies, 942 History; skeletal muscle relaxants; review, develop- K drugs, nonprescription; ingredients, product with- ments, 32 drawal, list, 88 HIV infections interleukin 2; renal cell carcinoma, single agent ther- acyclovir; chickenpox, herpes zoster therapy, HIV in- apy, FDA denial, 141 fections, 301 Ketoconazole; Cushing’s syndrome; therapy, mecha- latex; medical devices, allergies, recommendations, therapy; neutropenia, review, 268; research, AIDS nism of action, 12 417 conference, 809 Ketorolac tromethamine; use; evaluation, criteria, 715 Formulations Hodgkin’s disease; sargramostim; therapy, FDA ap- Kidney diseases; angiotensin-converting-enzyme in- cholestyramine resin; oral, palatability, vehicles, 138 provals, 411 hibitors; therapy, 25 colestipol hydrochloride; oral, palatability, vehicles, Hospitals; intensive-care units; delirium therapy, re- Kidney failure; vancomycin hydrochloride; chronic, 138 view, 456; patients, stress ulcer prophylaxis, DUE cri- blood levels, half-life, 297 Freezing; effects; phenytoin blood levels, ultrafiltration teria, 787 Klebsiella pneumoniae; resistance; ciprofloxacin, pneu- methods, 132 Hyperalimentation, see Nutrition; parenteral monia, 49 Vol10 Dec 1991 Clinical Pharmacy 983 Annual Index L desmopressin acetate; high dose, antidiuretic effects, Changes in federal programs for reporting suspected 912 adverse reactions to vaccines announced, 9 ketoconazole; Cushing’s syndrome therapy, 12 Conference attendees told ISIS-3 shows equal effi- Labetalol hydrochloride; hypertension; therapy, pedi- parasympathomimetic agents; Alzheimer’s disease cacy, safety differences among thrombolytics, 486 atrics, 500 therapy, review, 447 Consensus panel considers uses of botulinum toxin, Labor; terbutaline sulfate; preterm, home infusion ther- Melanoma; interleukin 2; therapy, 110 88 apy, 292 Memory disorders; therapy; Alzheimer’s disease, re- Consensus panel stresses need for greater awareness Lactation; drugs; patient information, excretion, re- view, 447 of panic disorder and its treatment, 893 view, 594 Meningitis; fluconazole; cryptococcal, therapy, DUE Consensus report focuses on hypertension during Latex; adverse reactions; allergies, FDA recommenda- criteria, 222 pregnancy, 93 tions, 417 Mercury Doxazosin approved as antihypertensive agent, 9 Laws; Anabolic Steroids Act of 1990; reclassification, poisoning; dimercaprol, N-acetyl-p,1-penicillamine, E5 antiendotoxin antibody reduces mortality among controlled substances, 417 antidotes, pediatrics, 213; toxicity, hyperthyroid- subset of patients with gram-negative sepsis, study Lead; poisoning; succimer therapy, 914; succimer ther- ism, 742 finds, 897 apy, FDA approvals, controversies, 942 Metabolism Enzyme replacement therapy approved for Lecithin; Alzheimer’s disease; therapy, mechanism of acetaminophen; acetimidoquinone metabolites, toxic- Gaucher's disease, 496 action, review, 447 ity, 765 Etodolac approved for marketing in the United Letters, 177, 257, 333, 429, 500, 664, 742, 823, 912 phenytoin sodium; impaired, liver diseases, activated States, 416 Antimicrobial dosages in guidelines for prevention of charcoal therapy, 711 FDA advisory committee reviews data suggesting bacterial endocarditis, 501 Metals; mercury; poisoning, hyperthyroidism toxicity, ethnic differences in response to zidovudine, rec- Correction to AHFS Drug Information 91, 913 742; poisoning, pediatrics, 213 ommends no changes in drug use, 326 Cryoprecipitate for uremic bleeding, 429 Methodology FDA bans 223 ingredients in nonprescription drug Dosage of antimycobacterial agents, 664 albumin human; dosage predictions, parenteral sup- products, 88 Ethnicity and clozapine-induced agranulocytosis, 743 plements, pediatrics, 704 Fludarabine approved for marketing, 496 Hyperthyroidism associated with mercury poison- antiarrhythmic agents; therapy, blood levels, moni- Gallium marketed for treatment of cancer-related ing, 742 toring, 211 hypercalcemia, 573 Interferon for genital warts, 177 cardiac drugs; monitoring, ventricular arrhythmia Guidelines for Pneumocystis carinii pneumonia pro- Inverse relationship between desmopressin dosage therapy, 195 phylaxis in children issued, 569 and antidiuresis, 912 creatinine; clearance, gentamicin excretion, renal Haemophilus b immunization recommendations up- Labetalol for treatment of hypertension in a child, 500 function estimation, 931 dated by American Academy of Pediatrics, 733 Laboratory monitoring of heparin therapy, 824 gentamicin; dosage predictions, pharmacokinetics, Highlights of the Seventh International Conference Pentamidine-induced facial numbness, 257 706 on AIDS, 809 Retreatment with digoxin immune Fab, 823 lithium carbonate; pharmacokinetics, models, 376 Intravenous quinidine recommended for severe Plas- Valproic acid hepatoxicity in adults and older chi meta-analysis; health data, applications and prob- modium falciparum malaria; injectable quinine dis- dren, 665 lems, 4 continued by CDC Drug Service, 653 Verapamil and left ventricular hypertrophy, 333 pharmacokinetics; computer programs, MS-DOS vs. Latex in medical devices may cause severe reactions; Leukemia Macintosh, 206 extra care advised, 417 fludarabine phosphate; B-cell, chronic, therapy, FDA phenytoin; dosage, pediatrics, pharmacogenetics, 928 Marketing of recombinant granulocyte-macrophage approvals, 496 warfarin; dosage predictions, nomograms vs. com- colony-stimulating factor approved by FDA, 411 sargramostim; lymphocytic, acute, therapy, FDA ap- puters, 923 New method of analyzing health data stirs debate, 4 provals, 411 Midazolam hydrochloride; use; review, criteria, quality New recommendations for prevention of bacterial Levamisole; colorectal neoplasms; therapy, review, 95 assurance programs, 388 endocarditis include amoxicillin use, 168 Lisinopril; kidney diseases; therapy, 25 Misoprostol News Briefs, 10, 94, 176, 253, 326, 417, 498, 573, 657, Lithium; neutropenia; therapy, HIV infections, review, interactions; ibuprofen, lack, 870 739, 822, 898 268 use; review, criteria, quality assurance programs, 307 Ondansetron granted marketing approval, 249 Lithium carbonate; pharmacokinetics; methodology, Models; pharmacokinetics; recainam, computer pro- Recombinant granulocyte colony-stimulating factor models, 376 grams, MS-DOS vs. Macintosh, 206 approved by FDA, 321 Liver cirrhosis; vancomycin hydrochloride; blood lev- Monoamine oxidase inhibitors; panic disorders; ther- Report assesses use of blood pressure monitoring els, half-life, 297 apy, 893 device- ‘or ambulatory patients, 175 Liver diseases; phenytoin sodium; impaired metabo- Moricizine; use; evaluation, arrhythmia therapy, crite- Report on pain management in childhood cancer lism, activated charcoal therapy, 711 ria, 873 published, 93 Lorazepam; dosage; sedation, amnesia, pediatrics, 625 Mortality; myocardial infarction; effects, thrombolytic Rubella prevention guidelines updated by CDC, 249 Lymphoma agents and aspirin, 486 Single large dose of intravenous immune globulin radionuclides; mon cional antibodies, 359 Muscle cramp; therapy; nocturnal leg cramps, 427 more effective than four-day regimen in patients sargramostim; non-Hodgkin’s, therapy, FDA approv- Mycobacterium avium complex; therapy; AIDS, review, with Kawasaki disease, investigators report, 657 als, 411 280 Study raises safety questions about B-agonist inhaler Myocardial infarction overuse, 822 aspirin and thrombolytic agents; comparisons, ther- Study shows effect of postmenopausal estrogen ther- apy, 486 apy on cardiovascular risk, 897 thrombolytic agents; comparisons, therapy, 486 Study shows efficacy of monoclonal antibody in pa- Magnesium sulfate; concomitant therapy, 292 tients with sepsis and gram-negative bacteremia, Manufacturing; valproic acid; emulsions, availability, 321 fresh vs. stored, 382 Transdermal fentanyl approved for chronic pain Marketing management, 9 alglucerase; FDA approvals, 496 Nafarelin; endometriosis; therapy, 518 Two cardiovascular agents, ramipril and isradipine, benazepril hydrochloride; FDA approvals, 739 National Cholesterol Education Program; protocols; approved for U.S. market, 573 doxazosin mesylate; hypertension therapy, FDA ap- hyperlipidemia therapy, 943 Two reports on hypertension available from National provals, 9 Nausea; ondansetron hydrochloride; therapy, DUE cri- Heart, Lung, and Blood Institute, 253 encainide hydrochloride; product withdrawal, toxic- teria, 471 Upcoming Specialty Meetings, 11, 94, 175, 326, 498, ity, 897 Negroes; psychotherapeutic agents; pharmacogenetics, 574, 657, 739, 822, 898 etodolac; osteoarthritis therapy, FDA approvals, 416 467 Year-end review shows 23 new drugs approved, 14 fentanyl; transdermal patches, FDA approvals, pain Neoplasms important biologic licensing actions taken by FDA, therapy, 9 radionuclides; monoclonal antibodies, 359 167 filgrastim; prophylaxis, neutropenia, FDA approvals, therapy; research, AIDS conference, 809 Niacin; hyperlipidemia; therapy, protocols, 943 321 Neutropenia Nicardipine; proteinuria; therapy, diabetic nephropa- fludarabine phosphate; FDA approvals, 496 filgrastim; prophylaxis, chemotherapy, FDA approv- thies, 862 gallium nitrate; FDA approvals, 573 als, 321 Nicotinic acid, see Niacin isradipine; FDA approvals, 573 therapy; HIV infections, review, 268 Nifedipine; angina pectoris; unstable, therapy, 825 ondansetron hydrochloride; prophylaxis, chemother- News, 4, 88, 167, 249, 321, 411, 486, 569, 653, 733, 809, Nitroglycerin; angina pectoris; unstable, therapy, 825 apy toxicity, FDA approvals, 249 893 Nomograms; warfarin; dosage, predictions, vs. comput- product withdrawal; nonprescription drugs, FDA American Academy of Pediatrics issues recommen- ers, 923 list, 88 dations on treatment of Lyme disease, 738 Nutrition; parenteral; albumin human, dosage predic- ramipril; FDA approvals, 573 Anabolic steroids reclassified as Schedule III con- tions, pediatrics, 704 sargramostim; FDA approvals, 411 trolled substances, 417 succimer; FDA approvals, controversies, 942 Benazepril approved for treatment of hypertension, Oo Mechanism of action 739 acetylcholinesterase inhibitors; Alzheimer’s disease Bristol discontinues sales of encainide, 897 therapy, review, 447 CAST II halted because of mortality trends, 897 Ofloxacin; effects; amikacin-resistant isolates, in vitro, amino acids; Alzheimer’s disease therapy, review, CDC offers recommendations for folic acid preven- 544 447 tion of neural tube defects, 898 Ondansetron hydrochloride analgesics; continuous epidural infusions, postopera- CDC publishes guidelines for anergy testing in HIV- approvals; prophylaxis, chemotherapy toxicity, 249 tive pain, 745; pain therapy, pediatrics, 667 infected persons, 653 pharmacology; review, 430 calcium antagonists; proteinuria therapy, diabetic CDC revises mefloquine dosage recommendations, use; review, criteria, quality assurance programs, 471 nephropathies, 862 417 Opiates 984 Clinical Pharmacy Vol 10 Dec 1991 Annual Index delirium; therapy, intensive-care units, 456 interleukin 2; review, 110 hetastarch; DUE criteria, 549 pain; postoperative, therapy, continuous epidural in- isradipine, 573 hyperlipidemia; therapy, National Cholesterol Edu- fusions, 745; therapy, pediatrics, 667 levamisole; review, 95 cation Program, 943 Osteoarthritis lithium carbonate; methodology, models, 376 ketorolac tromethamine; DUE criteria, 715 etodolac; therapy, FDA approvals, 416 ondansetron hydrochloride, 249; review, 430 midazolam hydrochloride; DUE criteria, 388 therapy; geriatrics, ulcer history, 740 phenytoin; dosage calculations, pediatrics, 928 misoprostol; DUE criteria, 307 phenytoin sodium; impaired metabolism, excretion, moricizine; arrhythmia therapy, DUE criteria, 873 P liver diseases, 711 ondansetron hydrochloride; DUE criteria, 471 psychotherapeutic agents; race, ethnic groups, 467 sargramostim; DUE criteria, 947 ramipril, 573 sufentanil citrate; DUE criteria, 635 recainam hydrochloride; computer programs, MS- vancomycin; dosage, neonates, 129 Pain DOS vs. Macintosh, 206 warfarin; thromboembolism therapy, 503 analgesics; postoperative, continuous epidural infu- sargramostim, 411 Psychotherapeutic agents sions, 745 skeletal muscle relaxants; review, mechanically venti- haloperidol; delirium therapy, intensive-care units, fentanyl; transdermal patches, therapy, FDA approv- lated patients, 32 456 als, 9 succimer; lead poisoning, therapy, 914 pharmacokinetics; race, ethnic groups, 467 ketorolac tromethamine; therapy, DUE criteria, 715 sufentanil; review, 581 Pulmonary surfactants therapy; acute, pediatrics, 667 triazolam; interactions, ranitidine, 539 alcohols, cetyl, combination, colfosceril palmitate, ty- Pancreatitis; pentamidine; toxicity, AIDS, hemophilia, valproate sodium; syrups, availability, vs. valproic loxapol; vs. beractant, therapeutic equivalency, 909 56 acid emulsions, 382 beractant; vs. cetyl alcohol-colfosceril-tyloxapol, Panic disorders; therapy, 893 valproic acid; emulsions, availability, vs. valproate therapeutic equivalency, 909 Paralysis; skeletal muscle relaxants; mechanically venti- sodium syrup, 382 lated patients, 32 vancomycin hydrochloride; relation, creatinine clear- Q Parasympatholytic agents; asthma; therapy, pediatrics, ance, 297 685 Pharmacy, institutional, hospital Parasympathomimetic agents; Alzheimer’s disease; quality assurance; programs, alfentanil, fentanyl, therapy, mechanism of action, review, 447 sufentanil, DUE criteria, 635; programs, enalapril, Quality assurance Parenterals, see Injections DUE criteria, 63; programs, erythropoietin, DUE hospital pharmacy; programs, alfentanil, fentanyl, Patches transdermal; fentanyl; pain therapy, FDA ap- criteria, 143, 303; programs, filgrastim, neutropenia sufentanil, DUE criteria, 635; programs, enalapril, provals, 9 prophylaxis DUE criteria, 950; programs, flucon- DUE criteria, 63; programs, epoetin, DUE criteria, Patient education; hypertension; ambulatory care, azole, DUE criteria, 222; programs, hetastarch, 143, 303; programs, filgrastim, neutropenia pro- monitoring, devices, 175 DUE criteria, 549; programs, ketorolac, DUE crite- phylaxis, DUE criteria, 950; programs, fluconazole, Patients ria, 715; programs, midazolam, DUE criteria, 388; DUE criteria, 222; programs, hetastarch, DUE crite- inpatients; gastrointestinal drugs, DUE criteria, 787; programs, misoprostol, DUE criteria, 307; pro- ria, 549; programs, ketorolac, DUE criteria, 715; moricizine, DUE criteria, 873 grams, moricizine, arrhythmia therapy, DUE crite- programs, midazolam, DUE criteria, 388; pro- latex; medical devices, allergies, FDA recommenda- ria, 873; programs, ondansetron, DUE criteria, 471; grams, misoprostol, DUE criteria, 307; programs, tions, 417 programs, sargramostim, DUE criteria, 947; pro- moricizine, arrhythmia therapy, DUE criteria, 873; outpatients; fluconazole, DUE criteria, 222; ketorolac, grams, stress ulcer prophylaxis, DUE criteria, 787 programs, ondansetron, DUE criteria, 471; pro- DUE criteria, 715; moricizine, DUE criteria, 873; Phenobarbital; epilepsy; therapy, review, 335 grams, sargramostim, DUE criteria, 947; programs, ondansetron therapy, DUE criteria, 471 Phenytoin stress ulcer prophylaxis, DUE criteria, 787 Pediatrics blood levels; effects, ultrafiltration and freezing, 132 Quality of life; thioridazine hydrochloride; generic albumin human; dosage predictions, parenteral sup- dosage; calculations, black African and Indian chil- equivalency, brands, comparison, 938 plements, 704 dren, 928 Quinidine; concomitant therapy, 823 analgesics; pain therapy, 667 epilepsy; therapy, review, 335 Quinolones asthma; therapy, 685 Phenytoin sodium; excretion; impaired, liver diseases, ciprofloxacin; susceptibility, amikacin-resistant iso- chloral hydrate; interactions, furosemide, 385 activated charcoal therapy, 711 lates, in vitro, 544 fluconazole; DUE criteria, 222 Phiebitis; injections; i.v. infusion sites, toxicity, 630 ciprofloxacin hydrochloride; interactions, warfarin, furosemide; interactions, chloral hydrate, 385 Physostigmine; Alzheimer’s disease; therapy, mecha- PT effects, lack, 136 ketorolac tromethamine; DUE criteria, 715 nism of action, review, 447 ciprofloxacin lactate; vs. ceftazidime, pneumonia and labetalol hydrochloride; hypertension therapy, 500 Pituitary hormones; desmopressin acetate; high dose, urinary tract infections therapy, 49 lactation; drugs, excretion, review, 594 mechanism of action, antidiuretic effects, 912 Mycobacterium avium complex; therapy, AIDS, review, lorazepam; dosage, sedation, amnesia, 625 Platelet aggregation inhibitors 280 mercury; poisoning, 213 aspirin; alone and with flurbiprofen, effects, 935 ofloxacin; susceptibility, amikacin-resistant isolates, neonates; pulmonary surfactants, therapeutic equiva- flurbiprofen; alone and with aspirin, effects, 935 in vitro, 544 lency, 909 Pneumonia ondansetron hydrochloride; therapy, DUE criteria, ceftazidime, comparison, ciprofloxacin lactate; noso- 471 comial, therapy, 49 phenytoin; dosage calculations, black African and In- ciprofloxacin lactate, comparison, ceftazidime; noso- dian children, 928 comial, therapy, 49 Race succimer; therapy, FDA approvals, 942 Poisoning patients; psychotherapeutic agents, pharmacogenet- vancomycin; neonates, dosage guidelines, 129 acetaminophen; overdose, acetylcysteine therapy, 765 ics, 467 Penicillamine; hepatolenticular degeneration; therapy, lead; succimer therapy, 914; succimer therapy, FDA pediatrics; phenytoin dosage calculations, 928 839 approvals, controversies, 942 Radionuclides; neoplasms; monoclonal antibodies, 359 Pentamidine; toxicity; pancreatitis, AIDS, hemophilia, mercury; dimercaprol, N-acetyl-p,1-penicillamine, Radiopharmaceuticals; neoplasms; monoclonal anti- 56 antidotes, pediatrics, 213; toxicity, hyperthyroid- bodies, 359 Pentamidine isethionate; adverse reactions; facial ism, 742 Ramipril; marketing; FDA approvals, 573 numbness, infusions, 257 Prescriptions; anabolic agents; steroids, reclassification, Ranitidine; ulcers; peptic, prophylaxis, osteoarthritis Pharmacists controlled substances, 417 therapy, geriatrics, 740 antiarrhythmic agents; therapy, blood levels, moni- Primidone; epilepsy; therapy, review, 335 Ranitidine hydrochloride; interactions; ibuprofen, lack, toring, 211 Product withdrawal 870; triazolam, pharmacokinetics, 539 arrhythmia; ventricular, therapy, monitoring, 210 drugs, nonprescription; ingredients, FDA list, 88 Rational therapy Pharmacodynamics; glyburide; effects, age, 532 encainide hydrochloride; toxicity, 897 cardiac drugs; ventricular arrhythmia therapy, 195 Pharmacogenetics Propoxyphene; and aspirin; pain therapy, codeine aller- pharmacists; ventricular arrhythmia, monitoring, 210 phenytoin; dosage calculations, pediatrics, 928 gies, 658 Recainam hydrochloride; pharmacokinetics; computer psychotherapeutic agents; race, ethnic groups, 467 Propylthiouracil; hyperthyroidism; therapy, mercury programs, MS-DOS vs. Macintosh, 206 Pharmacokinetics poisoning, 742 Reference books; lactation; drugs, patient information, alfentanil; review, 581 Proteinuria; calcium antagonists; therapy, diabetic review, 594 aminoglycosides; AIDS, 784 nephropathies, 862 Regulations analgesics; continuous epidural infusions, postopera- Prothrombin time Food and Drug Administration; nonprescription in- tive pain, 745; pain therapy, pediatrics, 667 ciprofloxacin hydrochloride; interactions, warfarin, gredients, withdrawal, 88 benazepril hydrochloride, 739 lack, 136 succimer; therapy, FDA restrictions, 942 doxazosin mesylate; hypertension therapy, 9 warfarin; interactions, ciprofloxacin, lack, 136 Replacement solutions; hetastarch; DUE criteria, qual- drugs; lactation, excretion, review, 594 Protocols ity assurance programs, 549 etodolac, 416 alfentanil hydrochloride; DUE criteria, 635 Reports fentanyl; and derivatives, review, 581; transdermal algorithms; ventricular arrhythmia therapy, 195 botulinum toxin type A; dystonia therapy, 88 patches, pain therapy, 9 enalapril maleate; DUE criteria, 63 drugs, adverse reactions; and toxicity, Vaccine Ad- filgrastim, 321 epoetin; DUE criteria, 143, 303 verse Event Reporting System, 9 fluconazole; review, 179 fentanyl citrate; DUE criteria, 635 hypertension; monitoring, devices, assessment, 175 fludarabine phosphate, 496 filgrastim; neutropenia prophylaxis, chemotherapy, Research gallium nitrate, 573 DUE criteria, 950 acquired immunodeficiency syndrome; therapy, gentamicin; dosage predictions, methodology, 706 fluconazole; DUE criteria, 222 AIDS conference, 809 glyburide; effects, age, 532 gastrointestinal drugs; stress ulcer prophylaxis, DUE hypertension; monitoring, devices, assessment, 175 ibuprofen; interactions, misoprostol, ranitidine, lack, criteria, 787 Resistance 870 heparin; thromboembolism therapy, 503 amikacin; gram-negative bacteria, in vitro, 544 Vol 10 Dec 1991 Clinical Pharmacy 985 Annual Index ceftazidime, comparison, ciprofloxacin lactate; pneu- brands, comparison, efficacy, quality of life, 938 Tranquilizers; thioridazine hydrochloride; generic monia and urinary tract infections, 49 Thromboembolism equivalency, comparisons, efficacy, quality of life, 938 ciprofloxacin lactate, comparison, ceftazidime; pneu- heparin; therapy, guidelines, 503 Transplantation; bone marrow; acute lymphoblastic monia and urinary tract infections, 49 warfarin; therapy, guidelines, 503 leukemia patients, sargramostim therapy, FDA ap- Respiratory distress syndrome; pulmonary surfactants; Thrombolytic agents; myocardial infarction; therapy, provals, 411; sargramostim therapy, DUE criteria, 947 therapy, therapeutic equivalency, 909 486 Triazolam; interactions; ranitidine, pharmacokinetics, Respiratory smooth-muscle relaxants; theophylline; Tissue levels; mercury; poisoning, pediatrics, 213 539 asthma therapy, pediatrics, 685 Tissue plasminogen activator, see Alteplase Trientine; hepatolenticular degeneration; therapy, 839 Restless legs; therapy; nocturnal, 427 Tocolytics; terbutaline sulfate; preterm labor, home in- Tyloxapol; combination, alcohols, cetyl, colfosceril Rhenium Re 188; radionuclides; monoclonal antibod- fusion therapy, 292 palmitate; vs. beractant, therapeutic equivalency, 909 ies, neoplasms, 359 Toxicity, environmental RS-86; Alzheimer’s disease; therapy, mechanism of ac- mercury; poisoning, occupational exposure, hyper- U tion, review, 447 thyroidism, 742; spills, inhalation, poisoning, pedi- atrics, 213 meta-analysis; methodology, applications and prob- Ulcers lems, 4 gastrointestinal drugs; stress, prophylaxis, DUE crite- Toxicity ria, 787 Salsalate; osteoarthritis; therapy, geriatrics, ulcer his- saecee taalmsoi nDorpuhgesn,; aodvveerrdsoes er,e aaccteitoynlsc ysteine therapy, 765 mpirsoopphryolsatxoils;; gpaespttriicc,, otshteeroaapryth,r iDtiUsE, gcerriitaetrriai,c s,3 077 40 alfentanil hydrochloride; DUE criteria, 635 Urinary tract infections Sclmuseaerr;ko edeteviranmlgau;a; t iFtoDhne,Ar acparypi;tpe rrosivay,as lte9sm4,i7 c 4,1 1 14 aannatsliigo-enissni,cf sl7;a4 5m;m saistdioedr ey eeffffeeaccgttsse,,n tsp;ca oinn toitsnhtueerooaauprsyt h,r ieptpeiidsdi uartratilhc se,ri anp6fy6u,7- cceifpatrpaoyzf,il do4ix9ma ec,i n colamcptaatrei,s ocno,m pacriiprsoofnl,o xacceifnt azliadctiamtee;; tthheerr-- Sex; patients; males, toxicity, i.v. infusion sites, 630 geriatrics, ulcer history, 740 apy, 49 Skeletal muscle relaxants antineoplastic agents; nausea and vomiting, ondanse- Urine levels; mercury; poisoning, pediatrics, 213 delirium; therapy, intensive-care units, 456 tron prophylaxis, 430; neutropenia, filgrastim pro- pharmacology; review, mechanically ventilated pa- pphhyyllaaxxiiss,, FFDDAA apapprporvoavlasl,s , 24392 1; ondansetron pro- Vv tients, 32 therapy; nocturnal leg cramps, restless legs, 427 bbeontauzleipnruiml htoyxdirno cthylpoer iAd;e ,s id7e3 9 effects, 88 Sorbitol; vehicles; activated charcoal therapy, cardiac drugs; ventricular arrhythmia therapy, 195 Vaccine Adverse Event Reporting System; vaccines; Stapbhielnityyt oin toxicity, liver diseases, 711 chl3o8r5a l hydrate; interactions, furosemide, pediatrics, Vacacdivneerss;e troexaicctiitoyn;s aanndd atdovxeicristey , rreeapcotritosn,s , 9 Vaccine Ad- ondansetron hydrochloride; review, 430 deferoxamine mesylate; side effects, hemochromato- verse Event Reporting System, 9 phenytoin; blood levels, freezing, ultrafiltration, 132 sis therapy, 775 Valproate sodium; comparison, valproic acid; stability, valspordoiicu m acsiydr;u p,e mu3l8s2i ons, availability, vs. valproate digiomxmiun;n ogtehneircapiyt,y , di8g2o3x in immune Fab retreatment, Valapvarioliacb ilaictiyd, emulsions vs. syrups, 382 Staphylococcus aureus; resistance; ciprofloxacin, pneu- doxazosin mesylate; side effects, hypertension ther- comparison, valproate sodium; stability, availability, Stemrooniidas,; 4a9n abolic agents; reclassification, controlled druagpsy;, 9l actation, 594 epielmeuplssy;i ontsh ervasp. y,s yrruepvsi,e w,3 823 35 substances, 417 enalapril maleate; DUE criteria, 63 Vancomycin; dosage; guidelines, neonates, 129 Steroids, cortico-; asthma; therapy, pediatrics, 685 encainide hydrochloride; side effects, product with- Vancomycin hydrochloride; blood levels; half-life, rela- Storage; effects; phenytoin blood levels, ultrafiltration drawal, 897 tion creatinine, hepatic and renal dysfunction, 297 Strmeeptthoocdosc,c us1 32 species; resistance; ciprofloxacin, pneu- eeptooedtoilna;c ; DsUiEde cerfifteecrtisa,, 411463 , 303 Vasdoiadsitloalitci ndgy safguenncttsi;o nh,e a8rt5 0 failure; congestive, therapy, Strmeopntioak,i n4a9s e; comparison, alteplase, anistreplase; my- fenatpayn,y l;9 side effects, transdermal patches, pain ther- Vehcihcolleess tyramine resin; palatability, oral formulations, Suocccairmdeiral infarction therapy, 486 ffielngtraansytli m;c itrnateeu;t rDoUpEen icar iteprirao,p h6y3l5a xis, DUE criteria, colpersetfieproel ncehsy,d ro1c3h8l oride; palatability, oral formula- mthaerrkaeptyi;n gl;e aFd DpAo isaopnpirnogv,a ls9,1 4 controversies, 942 flu9c5o0n; azsoildee ; effDeUctEs, 3c2r1it eria, 222; side effects, review, sortbiiotnosl,; parcetfievraetnecde s,c ha1r3c8o al therapy, phenytoin toxic- Sucralfate; use; evaluation, stress ulcer prophylaxis, cri- 179 ity, liver diseases, 711 SSuuffteeernnittaaa,n ni7il8l;7 cpihtarartmea; cousleo;g yr;e vi-eliwn,i caclr iutesreisa,, rqeuvaileiwt,y 5a8s1s ur- ffluur3do8as5r eambiidnee; pihnotseprahcattieo;n s,s idceh leofrfaelc tsh,y d4r9a6t e, pediatrics, VVeenrttiaiepnltaastm,o irlesf ;f ectssk,e le3t2a l muscle relaxants; mechanical, pa- ance programs, 635 gallium nitrate; side effects, 573 angina pectoris; unstable, therapy, 825 Surgical supplies; latex; adverse reactions, FDA recom- gastrointestinal drugs; stress ulcer prophylaxis, DUE muscle cramp; therapy, nocturnal leg cramps, 427 SymmBpe banltdohacotkileroysnt;si ,ca n4da1 g7e dnotxsa zosin, hypertension therapy, 9 hienjtcearcsitttieaorrnicash,;; 7i8.Dv7.U Ei nfcursiitoenri,a , ex5t4r9a vasation, phlebitis, 630 VViotclarumamimepn s ,o fE 4;2d 7i smtursicbluet ionc,r asmepe; Drutghse,ra pbyo,d y nodcitsutrrniabult iolne g scleroderma; systemic, therapy, 14 interleukin 2; side effects, neoplasms therapy, 110 Vomiting; ondansetron hydrochloride; therapy, DUE Sympathomimetic agents isradipine; side effects, 573 criteria, 471 ahesattrhitom na,;f a8i5tl0uhr eer;a pcyo,n gpeesdtiiavter,i cst, he6r8a5p y, diastolic dysfunc- klaebt5eo0tr0ao lloalc htyrdormoecthhlaomriidnee;; sDiUdeE efcfreitcetrsi,a , la7c1k5, pediatrics, Ww Syrpurposic; avcaildp reomautles isoondsi,u m3;8 2 stability, availability, vs. val- lead; poisoning, succimer therapy, 914 levamisole; side effects, colorectal neoplasms ther- Warfarin apy, 95 interactions; ciprofloxacin, PT effects, lack, 136 T lorazepam; side effects, high dose, pediatrics, 625 nomograms; dosage, predictions, vs. computers, 923 mercury; hyperthyroidism, long-term exposure, 742; thromboembolism; therapy, guidelines, 503 poisoning, pediatrics, 213 Weight; patients; predictions, lithium clearance, mod- Tacrine hydrochloride; Alzheimer’s disease; therapy, midazolam hydrochloride; DUE criteria, 388 els, 376 mechanism of action, review, 447 misoprostol; DUE criteria, 307 Taste; palatability; cholestyramine, colestipol, oral for- moricizine; arrhythmia therapy, DUE criteria, 873 mulations, 138 ondansetron hydrochloride; DUE criteria, 471; side X Terbutaline sulfate; labor; preterm, home infusion effects, 249; side effects, review, 430 therapy, 292 pentamidine; pancreatitis, AIDS, hemophilia, 56 Tests, laboratory phenytoin sodium; impaired metabolism, liver dis- Xanthomonas maltophilia; resistance; antibiotics, in phenytoin; blood levels, effects, ultrafiltration and eases, 711 vitro, 544 freezing, 132 ramipril; side effects, 573 prothrombin; warfarin, interactions, ciprofloxacin, sargramostim; DUE criteria, 947; side effects, 411 Y lack, 136 skeletal muscle relaxants; side effects, mechanically Theophylline; asthma; therapy, pediatrics, 685 ventilated patients, 32 TheArnaalpgye sCiocn suslelteacttiioonn , w1h2,e n4 27,t he6 58,p at7i4e0n,t 90i9s allergic to ssuufcecnitmaenri;l sciidter ateef;f ecDtUs,E lecardit eprioai,s o6n3i5n g therapy, 914 Yttrium Y 90; radionuclides; monoclonal antibodies, codeine, 658 terbutaline sulfate; side effects, preterm labor ther- neoplasms, 359 Comparing surfactant products, 909 apy, 292 Treatment of nocturnal leg cramps and restless leg thrombolytic agents; side effects, myocardial infarc- z syndrome, 427 tion therapy, 486 Treatment options for a patient with osteoarthritis vaccines; side effects, Vaccine Adverse Event Report- and a history of ulcer disease, 740 ing System, 9 Zidovudine; toxicity; neutropenia, HIV infections, re- Use of ketoconazole in the treatment of Cushing's zidovudine; neutropenia, HIV infections, review, 268 view, 268 syndrome, 12 Toxins; botulinum toxin type A; dystonia therapy, 88 Zinc; hepatolenticular degeneration; maintenance ther- Thioridazine hydrochloride; equivalency, generic; t-PA, see Alteplase apy, 839 986 Clinical Pharmacy Vol 10 Dec 1991 Annual Index Author Index A Dean, Roger P. Interaction of chloral hydrate and intra- Jermain, Donna M. Population pharmacokinetics of venous furosemide in a child, 385 lithium, 376 Dellamonica, Pierre Preventing recurrent varicella and Jirak, Jana L. see Vanderveen, R. Pete, 539 Allen, Nancy M. Retreatment with digoxin immune herpes zoster with oral acyclovir in HIV-seropositive Johanson, Franck see Dellmonica, Pierre, 301 Fab (letter), 823 patients, 301 Johnson, Juli A. Diastolic dysfunction in congestive Altman, Lawrence K. New method of analyzing health Dempsey, Robert J. see Rapp, Robert P., 49 heart failure, 850 data stirs debate (News), 4 Dixon, Dennis M. see Kowalsky, Steven F., 179 Johnston, Jann M. see Schwinghammer, Terry L., 532 Anderson, Bruce D. see Smith, Leanne B., 132 Donnelly, Andrew J. see Shafer, Amy L., 745 Jones, Paul R. see McMorrow, Julie, 501 Anderson, Philip O. Drug use during breast-feeding, Dressman, Jennifer B. see Knapp, Margaret J., 866 Jones, William N. see Rindone, Joseph P., 136 594 Dufresne, Robert L. see Bablenis, Elena, 938 Antal, Edward J. see Schwinghammer, Terry L., 532 K Ariano, Robert E. Inverse relationship between e desmopressin dosage and antidiuresis (letter), 912 Asher, John P. Use of angiotensin-converting-enzyme inhibitors in the management of renal disease, 25 Kaatz, Brian L. see Fischer, Janet R., 292 Eaton, Virginia E. see Rathbun, R. Chris, 280 Kelleher, Michael D. see Dean, Roger P., 385 Keller, James H. Book review, 239 Kelley, Catherine L. see Rindone, Joseph P., 136 Khanderia, Ujjaini Use of ketoconazole in the treat- ment of Cushing’s syndrome (Therapy Consultation), Bablenis, Elena Effect of use of generic thioridazine 12 products on clinical outcome and quality of life, 938 Fischer, Janet R. Continuous subcutaneous infusion of Kildoo, Carl W. III see Gabriel, Mariane Hardenbrook, Banner, William Jr. Succimer: controversial issues in- terbutaline for suppression of preterm labor, 292 129 volving the release of a new product (editorial), 942 Fish, Douglas N. Treatment of delirium in the critically Kintzel, P. E. Recombinant interleukin-2: a biological Barnett, Michael D. see McGee, Barbara A., 14 ill patient, 456 response modifier, 110 Basile, Sharon A. Criteria for use of hetastarch, 549 Fish, Susan S. Book review, 730 Kirking, Marilyn H. Treatment of chronic iron over- Baumann, Terry J. Analgesic selection when the patient Florentine, Mauro J. Elemental mercury poisoning, 213 load, 775 is allergic to codeine (Therapy Consultation), 658 Floriddia, Donald G. Book review, 649 Klutman, Neil E. see Henry, David W., 625 Beail, Barbara see Matsuyama, Joy R., 544 Forrest, Alan see Weidle, Paul J., 711 Knapp, Margaret J. Modification of gastric pH with oral Bennett, Teresa A. Criteria for use of epoetin, 143, 303 Fredriks, Dean A. Nomogram for dosing warfarin at glutamic acid hydrochloride, 866 Bennett, Teresa A. Criteria for use of moricizine in steady state, 923 Knight, Matthew E. see Veerman, Mark W., 382 adult inpatients and outpatients, 873 Kolb, Kenneth W. see Walton, Ted, 427 Berardi, Rosemary R. see Knapp, Margaret J., 866 G Kowalsky, Steven F. Fluconazole: a new antifungal Bernard, Evelyne see Dellamonica, Pierre, 301 agent, 179 Bhatt-Mehta, Varsha Management of acute pain in chil- Kresel, James J. Book review, 243 dren, 667 Gabriel, Mariane Hardenbrook Prospective evaluation Kubacka, Reneé T. see Schwinghammer, Terry L., 532 Billeter, Marianne see Rapp, Robert P., 49 Bombardt, Paul A. see Vanderveen, R. Pete, 539 Garofa bae dviaannc-oRmuyfcfianl o,do sSaugsea ng uiMd.e lisneee Sfaolrt inele,o naEtmemsa,n u1e2l9 , L Bond, William S. Ethnicity and psychotropic drugs, 467 518 Botha, Julia H. Estimating phenytoin dosages in black Garewal, Harinder S. see Rindone, Joseph P., 136 BouArfnreic,a nD aavnidd IWn.di aAn. csehei ldHraemn,p t9o2n8, Edward M.., 206 Garnett, William R. see Pugh, Carol B., 335 Lackner, Thomas E. A nonexponential, nonlogarithmic, Bouardnulet, aKnidm bpeerdilayt riMc. iCnrpiatteireinat sf oar ndus eo uotfp aftliuenctosn,a zo2l2e2 in Gen1n2r9 ich, Jane L. see Gabriel, Mariane Hardenbrook, Lewpihsa,r maRciochkairnde tiKc. dAosssiensgs mmeentth oadn df ort rgeeanttmaemnitc ino,f a7c0e6t - BBuucbr3kl2w, oi cnkMkialnregc, i aaJ goeLsn.e tpUshs e i Wno .f m ensecoehn adHneeipncoralyla,lr yi zDiavnveignd t inlWea.ut,er do 6m2u5psa tciuelnatsr, GGGGiioollraloam,nd ,adw Mn ia,Mon rla,dkrJ e yarSm A.i.c L ehDe siaielT aed. nB reoNeV aonak klsa pe(herlr ieoetriBvtocoei r,ue) rwa,n ,cRie 6ad,68n 50dh 5aKe liplma btoeKt.r,ol xy9i 3c1iM t.,y 2i2n2 adults LLLioonkan(,ilgm eelitcAetn,ney ron,)pF,e rh Ja2eon5Ynyc.7 co eioF .sv eMPrs.ede neo tsAaeDl,met elirld7eai6dm5n o en-aiimcniadn,uo cgPleiydec rorefs,ai cdi3ae0l 1 vnoulmubmnee sso f Graves, David A. Book review, 970 distribution in patients with acquired immunodefi- Cc Green, Elaine R. Book review, 729 ciency syndrome, 784 Lopez, Larry M. Verapamil and left ventricular hy- H pertrophy (letter), 333 Calis, Karim Anton see Kintzel, P. E., 110 Carles, Michel see Dellamonica, Pierre, 301 Carter, Barry L. Therapy of acute thromboembolism Hackimer, Mary E. see Schwinghammer, Terry L., 532 with heparin and warfarin, 503 Carver, Peggy L. see Knapp, Margaret J., 866 HHaakm,p tLoanw,r enEcdew aJr.d s ee MO.' NeCiolm, paMriichsaoenl Go.f, 5M6S -DOS and Mann, Katherine V. Succimer, an oral lead chelator, 914 CCChhhaaeostfefchhf ,kroae ,owne Jmst,obi WoaeilnBmlyeneetlttqetiiiu yccaaS slm. J a.sg( eOeAeNen.nfe t fdwsNisa,Cca) anok,cnsa4y 3fhe,04ie t 8rrr6oeo s,nan cf—eeRtt ayhn eadta tldeilfinf rfdsKeet. re,eos nf 9 c3ea1t s on led wa mIcSolInaSs-gs3 HHaaraMash tdayetwucdgwliiratogon w-,ctao chou,olst Smohptpr aeGiatvpdirueheetynan m tresimnR,nCa .t .c , a4od 7AkCu1nritl ittnwti oeea-trariiinrnacd hf uyasftpnoiheraomd lniiya ucsts diresoi smc oiponnfriig ont pgoosarnrtcadiihamneensgnm:s te szu isvmai2ionn0sndg6- MMMMaaaarrrpttttthosiii iulnnnni,,y,ea aw emEEJa.rammn Kd,ooe rralnyyaJlt moyiiy mSSk ..iJa rcRc.II.r IIi oBIInSb o-uissorsaeekceeele sspi,Jarts leeistrvb5oamii4 nae4ltiRw i na,t, tyg h9rbD7oauf6omn n-X,nna aenR gt.ah MtoC.ihm,rvo ien3s a7,6s b a2c8mt0ae lrtioa- CCClhooicattnhrnz,ard, ta inAoaMl,nlif fcreEhneamtadfati enellirsy l e ,e AaB.l.N5 b8aCP1ukl rmaieihndiniirc caotl,is ounupR spaeolnsfde amsoleefln r tufaKme.tn ,ti aao9nln3yb1 l u,m iins nu fpeecndotinaacnteirnli-,c HHHHaaeettcnpttklrooeaynnrc,,,,e d JDRJiaeaomvmnhimpnddih y as sesWCeie ..es W srReD(iaeeeg pdthipVett,ero, erm irRiaAomnllba)aee,ntx r,i,t2 o 1n61M3 P .a0, ro f4k 9 sWe.d,a ti3v8e2 and am- MMMMaacctymCCt,eoah rlnecJlnw.ua, ,rRm y u,s EsMapeiProlcalil ths raBoi.eBnc lokis o nekegL H.R yr(Eaeplvtevetahirtlbeeturwuh)a,n,yt , ri 87oo84Rni52. d iCahsnrmdi s,t rase2sa8ot0cm ieantte do f wvietnh- patients receiving parenteral nutrition, 704 nestic doses of lorazepam in children, 625 tricular arrhythmias: an update, 195 Coleman, Robert W. see Fredriks, Dean A., 923 Hogue, Susan L. see Cochran, Emily B., 704 McGee, Barbara A. Current options for the treatment of Coley, Allison L. Criteria for use of enalapril maleate in Housel, Ben F. see Ishisaka, Denis Y., 500 systemic scleroderma, 14 adults, 63 Hrdlicka, Kyle see Hampton, Edward M., 206 McGee, Barbara A. see also Small, Ralph E., 870 Collins, Shelly Rainforth see Gabriel, Mariane Harden- Hutson, Paul R. see Mutch, Rebecca S., 95 McMorrow, Julie Antimicrobial dosages in guidelines brook, 129 for prevention of bacterial endocarditis, 501 CCooomnscteo,c k,S haTnhnoomna s L.J .s eBeo oMku rrpehvyi,ew ,C h8r9i0s tine M., 685 MMeednidneal,, RSitcehpahredn AB.o oskee rPeevtieerws,, M80a5r k D. II, 787 Cortese, Linda M. Criteria for use of midazolam hydro- Michael, Katherine A. see Peters, Mark D. II, 787 CCCoorxuic(,lhcse lhmtot,Soret nrie,)d,v Pe ea M4nt2.ir n9i cR La.idy au snlenetC rVsypeaaoetpn irdeJeenecrtrisvmp,ea iiet3nna8,,t8 e DRo. nfoPnrea t e,u Mr.e5,3m 9i3 c7 6 bleeding IIIstsorhsh,aii eusolMam,nk aaatinD,nt e habDi e emcwnhm iiSu.lsn dK o.NYd (e.leu AefttcLticraecebor)piep,ttee aann5lbci0oiya0ll itfvyioi nrr uostpf,ra tecia2eh6tn8mot elsne ts tiynofrfea cmhtiyenpdee r tweainnt-hd MMMMiiiolllCodlllsoaeeetnrrrnes,,,lou aolrADRtutloaa,hantry niaim otloniBdHs)n. o, d suRa e.cn7e 4d shT0e aBre ean e ngaBnhtoeeitmt shetta,no, rtD y T.J e uoorlpfeit ssaieu aelo H cn.eAs,r. G, 9 afd2o8bi8rr7s i3eae a lsp,ea ti(eMTnahtre irwaaipntyeh D colestipol formulations in three common vehicles, 138 Hardenbrook, 129 Mondain, Véronique see Dellamonica, Pierre, 301 J Moodley, Manikum see Botha, Julia H., 928 Davenport, Robertson Cryoprecipitate for uremic Morreale, Anthony P. see Ito, Matthew K., 138 bleeding (letter), 429 Murphy, Christine M. Treatment of asthma in children, Davis, Lisa E. see Spinler, Sarah A., 825 Jacobi, Judith Book review, 80 685 Vol 10 Dec 1991 Clinical Pharmacy 987 Annual Index Murray, Kim M. Calcium-channel blockers for treat- plex disease, 280 pertrophy (letter), 333 ment of diabetic nephropathy, 862 Reed, Michael D. see Buck, Marcia L., 32 Tibbs, Phillip A. see Rapp, Robert P., 49 Murray, Kim M. see also Asher, John P., 25 Reilly, Raymond M. Radioimmunotherapy of inalig- Todd, Mark W. Criteria for use of misoprostol, 307 Mutch, Rebecca S. Levamisole in the adjuvant treat- nancies, 359 Todd, Mark W. see also Bennett, Teresa A., 143, 303 ment of colon cancer, 95 Rider, Joan M. see Knapp, Margaret }., 866 Travers, John D. see Mann, Katherine V., 914 Rindone, Joseph P. Hypoprothrombinemic effect of Trotter, J. Mark see Bennett, Teresa A., 873 warfarin not influenced by ciprofloxacin, 136 RRousdeinn,s kDya,v iBdr iaAn. sFe.e seBeh aDteta-nM,e htRao,g erV arP.s,h a3,8 5 667 U Rutledge, David R. Which lipid-lowering agent should Nahata, Milap C. see Clotz, Michael A., 581 be used first? 943 Nahata, Milap C. see also McMorrow, Julie, 501 Uden, Don Book review, 650 Nakahiro, Randall K. Use of gentamicin clearance in Ss estimating renal function, 931 Vv Nappi, Jean Trials and tribulations of evaluating ven- tricular arrhythmias (editorial), 210 Saltiel, Emmanuel Pharmacologic management of en- Newby, F. David see Longley, Joyce M., 784 dometriosis, 518 Vanderveen, R. Pete Effect of ranitidine on the disposi- Sandroni, Stephen see Bennett, Teresa A., 143, 303 tion of orally and intravenously administered Oo Sanfilippo, Dominic J. II see Florentine, Mauro J., 213 triazolam, 539 Satterlee, Grant B. Criteria for use of fentanyl citrate, Veerman, Mark W. Relative bioavailability and stabil- sufentanil citrate, and alfentanil hydrochloride, 635 ity of extemporaneously prepared valproic acid Scheckner, Stuart see McCann, Michael, 742 emulsion, 382 O'Neil, Michael G. Pancreatitis during pentamidine Scholten, Stephanie L. Correction to AHFS Drug Infor- Volger, Burgunda W. Alternatives in the treatment of therapy in patients with AIDS, 56 mation 91 (letter), 913 memory loss in patients with Alzheimer’s disease, Okamoto, Mark P. see Nakahiro, Randall K., 931 Schwinghammer, Terry L. Pharmacokinetics and phar- 447 Orlando, Patricia L. Book review, 885 macodynamics of glyburide in young and elderly Volger, Burgunda W. Book review, 317 nondiabetic adults, 532 P Sclar, David A. see Nakahiro, Randall K., 931 Ww Selub, Steven E. see O'Neil, Michael G., 56 Seymour, Beverly see Ariano, Robert E., 912 Pachorek, Robert E. Vancomycin half-life in a patient Shacfoenrt,i nAuomuys Le.p iMdaurnaalg eimnefunsti on ofo fp oasntalogpeesriactsi,v e7 45p ain by Wallis, Carolyn see Matsuyama, Joy R., 544 with hepatic and renal dysfunction, 297 Walton, Ted Treatment of nocturnal leg cramps and Paloucek, Frank P. see Lewis, Richard K., 765 Shepherd, Michele F. Criteria for use of ketorolac tro- restless leg syndrome (Therapy Consultation), 427 PPPPaaeertrlaiekogsreqeshrun,,,it nsGR, Rao o(ryblye eCt rtChte.Rar .r) s,lBe se.ee6 s e6s P4eVei naAcn.Mu dcseC,rD ovolKesleeaalnglm,ye, TR.P.,oa ft 9Pr3eit5ace nk,t i5Lm.3,y9 c 1o9b5a cterial SSSSkjkiioommelroesaanttn,,,hd aeIDrmPra,aien mnnieJeee ul llAa ii. en J .AsAa .es.d ee u esls eSteeaWe t etMiiePnudreplrltaeeepter,hi,s e y,n ,PGta Mrsuaa Clnrh atkrnJ i .d,s B Dt.7.o,i1 u1n6 teI3Ip ,5a M7t.8i,7e n6t8s5, 715 WWWeeeiibj7dse1usl1nr c,e,t , PSetPtthaaeeunrlrl aeDpyJ.y. MsSe.uae lf stteeLierap clBkecanh-berdlrooe,nns iiecs T ,h aocpEtmhliaeevnnsaay t,te Edo.9 i,3 nc87 h 0a6ir nctooaxli caats ioand,- PPPPPPPeiolirrtrniateipuetccivtnlcreeu somats,rsaistas, ,,nent n lct,,(KeMDe e TtKa,nao heD RsrrnelaioeeKk lrgvbnna yegaea Rr- rp.clDece ycTd.Oang B.a rva o CeetIoGoE IIrik.. fnRso fp C sostnearuesgr,crtieeltee iet et eeevr 9aInrtis3otsLtie fr5isaowa ,on,eC nfEgl of,t)ll7o mh3u,e8rn1r pDy 7i6b ,eas9c i tbr0ipr 9tiJre yosSon .syfg, ce ena2u n6lsdc8Muae .rrn,f d ca p7lc8orta4zaos anpptphi iyrnilpena-r xioiondsn-- SSSSSSmmmmppaariiiiduallunttblenlillhhtutgl,,e,,rpeil r arr,n,fRR omaC Liafai aWSellenlintapaanpplrdernt hhcalaani ttiphceooi haEeEn ro.am,i ,An r s. B-s,sEm .efJef a e1Ar.ef c38 e dEes22ofeacveL 5fkltzeai essii ncn onn,tP cg e oie MtfAnos cicnfs mcGun esiseeiu,qs,en l uo ,tpetYKr 8hr.nae7e ofclB0 isFlea l.ttyr ,tr o bre2laTaoa5. rtnt,7ia m oo 9renf3 nAr5t.re ,p ea r no1oipf4tdh iuuedcnnitsyn teta oabinolnnde WWWWWWWieiiroolllittnetoltmgithigdxyoohsek,,,tnt,troa r-,alwPT apH FsRayiavrCkAot meyaoylbedoen(se,ereltsfx ra,ereh tt titAryacEeiIneM .rkno)n ne f,E6nscJ l .ue.s3e, soe e8K0 B ie2d,H o o4 Soiyno mnPLg ka ahal GclbAfl.hioarI, iogre DlsrhavSueRtetire askeoe ,lw r(S ,pyNmco h eaRfa wlo 1umslb5Esot,.)9eehn, , rde i t 8 Rt 7a8oS0b0lEre 9y.pvi, h en 2png9htE l7.he, o bf8i 7tIh0ine stp earraninand- duced agranulocytosis (letter), 743 Sta(hllet-tBear)y,l is1s7,7 Celine M. Interferon for genital warts Pugh, Carol B. Current issues in the treatment of epi- Swanson, Keith A. see Peters, Mark D. II, 787 Y lepsy, 335 Pugh, Carol B. see also Smith, Leanne B., 132 T Yamreudeewong, Weeranuj see Lackner, Thomas E., 706 Yonan, Charles D. see Ishisaka, Denis Y., 500 Tami, Joseph A. Recombinant interleukin-2 and the Young, A. Bryon see Rapp, Robert P., 49 quest for FDA approval, 141 Rapp, Robert P. Intravenous ciprofloxacin versus cef- Tankanow, Roberta M. Pathophysiology and treatment tazidime for treatment of nosocomial pneumonia and of Wilson's disease, 839 Z urinary tract infection, 49 Tankanow, Roberta M. see also Chaffee, Betty J., 430 Rathbun, R. Chris Current and investigational thera- Tartaglione, Teresa see Matsuyama, Joy R., 544 pies for AIDS-associated Mycobacterium avium com- Thom, Claire M. Verapamil and left ventricular hy- Zeleznik, Dee see Matsuyama, Joy R., 544 988 Clinical Pharmacy Vol 10 Dec 1991